[HTML][HTML] Effectiveness and safety of extended treatment with direct oral anticoagulants for venous thromboembolism in Japan: A retrospective cohort study using claims …
H Hashimoto, S Imai, A Kiyomi, M Sugiura - Thrombosis Update, 2022 - Elsevier
Purpose We aimed to evaluate the risk of recurrent venous thromboembolism (VTE) among
patients receiving direct oral anticoagulant (DOAC) therapy (extended and non-extended) …
patients receiving direct oral anticoagulant (DOAC) therapy (extended and non-extended) …
Case fatality rates of recurrent thromboembolism and bleeding in patients receiving direct oral anticoagulants for the initial and extended treatment of venous …
A Gomez-Outes, R Lecumberri… - Journal of …, 2015 - journals.sagepub.com
Background: In patients with venous thromboembolism (VTE), the study of the case fatality
rate (CFR) of VTE recurrences and bleeding complications may be of help to balance the …
rate (CFR) of VTE recurrences and bleeding complications may be of help to balance the …
Clinical outcomes of direct oral anticoagulants vs warfarin for extended treatment of venous thromboembolism
MC Fang, K Reynolds, D Fan, PA Prasad… - JAMA Network …, 2023 - jamanetwork.com
Importance Extending the duration of oral anticoagulation for venous thromboembolism
(VTE) beyond the initial 3 to 6 months of treatment is often recommended, but it is not clear …
(VTE) beyond the initial 3 to 6 months of treatment is often recommended, but it is not clear …
[HTML][HTML] Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants
K Kaneda, Y Yamashita, T Morimoto, R Chatani… - European Journal of …, 2023 - Elsevier
Background There has been limited data on anticoagulation strategies and long-term
recurrence in patients with venous thromboembolism (VTE) in the era of direct oral …
recurrence in patients with venous thromboembolism (VTE) in the era of direct oral …
Temporal Changes in Long‐Term Outcomes of Venous Thromboembolism From the Warfarin Era to the Direct Oral Anticoagulant Era
K Kaneda, Y Yamashita, T Morimoto… - Journal of the …, 2024 - ahajournals.org
Background There have been limited data on the changes in clinical outcomes after the
introduction of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) in …
introduction of direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) in …
Venous thromboembolism recurrence among one-and-done direct oral anticoagulant users: a retrospective longitudinal study
M Alberts, M Zhdanava, D Pilon… - International Journal of …, 2023 - Springer
Abstract Background Direct oral anticoagulants (DOACs) are the American Society of
Hematology guideline-recommended treatment for venous thromboembolism (VTE) in the …
Hematology guideline-recommended treatment for venous thromboembolism (VTE) in the …
Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens
J Trujillo-Santos, P Di Micco, F Dentali… - Thrombosis and …, 2017 - thieme-connect.com
In patients with venous thromboembolism (VTE), the influence on outcome of using direct
oral anticoagulants (DOACs) at non-recommended doses or regimens (once vs twice daily) …
oral anticoagulants (DOACs) at non-recommended doses or regimens (once vs twice daily) …
[HTML][HTML] Extended DOAC therapy in patients with VTE and potential risk of recurrence: A systematic review and meta‐analysis
M Ebraheem, I Alzahrani, M Crowther… - Journal of Thrombosis …, 2020 - Elsevier
Background Guidelines recommend at least 3 months of anticoagulation for venous
thromboembolism (VTE). Evidence supporting indefinite anticoagulation exists in certain …
thromboembolism (VTE). Evidence supporting indefinite anticoagulation exists in certain …
Hospital length of stay in patients initiated on direct oral anticoagulants versus warfarin for venous thromboembolism: a real-world single-center study
H Badreldin - Journal of Thrombosis and Thrombolysis, 2018 - Springer
This study was conducted to describe the real-world hospital length of stay in patients
treated with all of the US Food and Drug Administration approved direct oral anticoagulants …
treated with all of the US Food and Drug Administration approved direct oral anticoagulants …
Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review
C Wu, GS Alotaibi, K Alsaleh, MS McMurtry - Thrombosis research, 2014 - Elsevier
Introduction The frequency and case fatality of venous thromboembolism (VTE) and major
bleeding during the initial 3 months of therapy in those treated for symptomatic VTE with …
bleeding during the initial 3 months of therapy in those treated for symptomatic VTE with …